[Clinical and hemodynamic effects of medium-term treatment with muzolimine in subjects with essential arterial hypertension].
The antihypertensive effects and haemodynamic changes after administration of 30 mg/die of muzolimine for 30 days in a group of patients with mild or moderate essential hypertension have been evaluated. Our findings showed a significant reduction of body weight, arterial blood pressure, systemic vascular resistance, plasma volume and small but significant increase of left ventricular ejection fraction. No relevant side effect have been observed.